Review article · 2015 · Open access
Advances in Alzheimer’s Disease Drug Development
BMC Medicine, 13(1), 62 · Published 25 March 2015 · DOI 10.1186/s12916-015-0297-4
In brief
“Advances in Alzheimer’s Disease Drug Development” is a 2015 review article by Michael S. Rafii and Paul S. S. Aisen, published in BMC Medicine. OpenAlex counts 98 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at BMC Medicine.
- Citations
- 98
- Most cited in
- 2016 (28)
- Field-weighted impact
- 2.01
- References
- 46
- Authors
- 2
Abstract
Alzheimer's disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional dependency. Recent biomarker studies indicate that AD is characterized by a long asymptomatic phase, with the development of pathology occurring at least a decade prior to the onset of any symptoms. Current FDA-approved treatments target neurotransmitter abnormalities associated with the disease but do not affect what is believed to be the underlying etiology. In this review, we briefly discuss the most recent therapeutic strategies being employed in AD clinical trials, as well the scientific rationale with which they have been developed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Rafii, M. S., & Aisen, P. S. S. (2015). Advances in Alzheimer’s Disease Drug Development. BMC Medicine, 13(1), 62. https://doi.org/10.1186/s12916-015-0297-4
MLA 9
Rafii, Michael S., and Paul S. S. Aisen. “Advances in Alzheimer’s Disease Drug Development.” BMC Medicine, vol. 13, no. 1, 2015, p. 62. https://doi.org/10.1186/s12916-015-0297-4.
Chicago
Rafii, Michael S. and Paul S. S. Aisen. 2015. “Advances in Alzheimer’s Disease Drug Development.” BMC Medicine 13 (1): 62. https://doi.org/10.1186/s12916-015-0297-4.
Harvard
Rafii, M. S. and Aisen, P. S. S. (2015) ‘Advances in Alzheimer’s Disease Drug Development’, BMC Medicine, 13(1), p. 62. doi:10.1186/s12916-015-0297-4.
IEEE
M. S. Rafii and P. S. S. Aisen, “Advances in Alzheimer’s Disease Drug Development,” BMC Medicine, vol. 13, no. 1, p. 62, 2015, doi: 10.1186/s12916-015-0297-4.
BibTeX
@article{rafii2015advances,
title = {{Advances in Alzheimer’s Disease Drug Development}},
author = {Rafii, Michael S. and Aisen, Paul S. S.},
journal = {BMC Medicine},
year = {2015},
volume = {13},
number = {1},
pages = {62},
doi = {10.1186/s12916-015-0297-4},
url = {https://doi.org/10.1186/s12916-015-0297-4}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 28 | |
| 2017 | 9 | |
| 2018 | 16 | |
| 2019 | 6 | |
| 2020 | 12 | |
| 2021 | 6 | |
| 2022 | 6 | |
| 2023 | 6 | |
| 2024 | 3 | |
| 2025 | 1 |
Its field-weighted citation impact is 2.01: it has been cited 2.01 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development
- dementia
- memory impairment
- biomarkers
- asymptomatic phase
- neurotransmitter abnormalities
- clinical trials
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Rafii, M. S., & Aisen, P. S. S. (2015). Advances in Alzheimer’s Disease Drug Development. BMC Medicine, 13(1), 62. https://doi.org/10.1186/s12916-015-0297-4
How many times has this paper been cited?
98 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at BMC Medicine.
Who wrote this paper?
Michael S. Rafii, Paul S. S. Aisen.
What is the DOI of this paper?
10.1186/s12916-015-0297-4. The permanent link is https://doi.org/10.1186/s12916-015-0297-4.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.